Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $2.32 Analyst target: $10.33 Upside: 345.26%
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of candidate products for the treatment of diseases of the central nervous system. The company is headquartered in Waltham, Massachusetts.
See the full interactive analysis & chart →Informational only — not investment advice.